IL2 and obesity due to melanocortin 4 receptor deficiency: This strategy is a novel IL-2 drug design for biologic therapy using FA to alter the immunologic, pharmacokinetic, and biodistribution profile of IL-2; the same strategy has been successfully applied to semaglutide: a once per week GLP-1 agonist for treating diabetes and obesity [30,31].